



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	Suthanthiran, et al.	Examiner:	Unassigned
Serial No.:	10/627,408	Group Art Unit:	1642
Confirmation No:	2823	Docket:	955-10 P/CON/DIV
Filed:	July 25, 2003	Dated:	October 29, 2003
For:	USE OF ANGIOTENSIN II INHIBITORS TO PREVENT MALIGNANCIES ASSOCIATED WITH IMMUNOSUPPRESSION		

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

*I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313 on October 29, 2003*

Signature: Nicole R. Spore

INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R. §1.56, Applicants submit herewith the following Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

NON-PATENT PUBLICATIONS

1. M. Maluccio, et al., "Angiotensin II Receptor Blockade: A Novel Strategy to Prevent Immunosuppressant-Associated Cancer Progression", *Transplantation Proceedings* (2001) Vol. 33, pp. 1820-1821.
2. Hojo, et al., "Cyclosporine induces cancer progression by a cell-autonomous mechanism", *Nature* (1999) Vol., 397, pp. 530-534.


3. Gary J. Nabel, "A transformed view of cyclosporine", *Nature* (1999) Vol. 397, pp. 471-472.
4. Khanna, et al., "Regulation of new DNA Synthesis in Mammalian Cells by Cyclosporine", *Transplantation* (1994) Vol. 57, pp. 577-582. (Abstract)
5. Kim, et al., "Immunosuppressive effects of 2-acetylaminofluorene and 2-aminofluorene on murine splenocytes culture", *Drug Chem Toxicol* (1989) Vol. 12, pp. 297-311. (Abstract)
6. Tschmelitsch, et al., "Enhanced antitumor activity of combination radioimmunotherapy (¹³¹I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil)", *Cancer Res* (1997) Vol. 57, No. 11, pp. 2181-2186. (Abstract)
7. Baselga, et al., "Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies", *J. Natl. Cancer Inst.* (1993) Vol. 85, No. 16, pp. 1327-1333. (Abstract)
8. Wolf, et al., "Angiotensin II-induced Hypertrophy of Cultured Murine Proximal Tubular Cells is Mediated by Endogenous Transforming Growth Factor- β ", *J. Clin. Invest.*, (1993) Vol. 92, pp. 1366-1373.
9. Paine-Murrieta, et al., "Human tumor models in the severe combined immune deficient (*scid*) mouse", *Cancer Chemother Pharmacol* (1997), Vol. 40, pp. 209-214.
10. Volpert, et al., "Captopril Inhibits Angiogenesis and Slows the Growth of Experimental Tumors in Rats", *J. Clin. Invest.* (1996) Vol. 98, pp. 671-679.

The above-referenced documents are listed on PTO Form 1449. We have enclosed the cited documents to facilitate reference to them. The Examiner is respectfully requested to consider these publications in their entirety, and to indicate that he or she has done so by initializing the enclosed form PTO 1449.

The Information Disclosure Statement is submitted before the first Office Action, therefore, it is believed that no fee is due. However, if a fee is due, the Commissioner is hereby authorized to charge any fees associated with this communication to Deposit Account No. 08-2461. A duplicate copy of this paper is attached for that purpose.

Applicants are not aware of any other references to be identified at this time. If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicants' agent at the telephone number set forth below.

Respectfully submitted,



Edna I. Gergel, Ph.D.

Registration No.: 50,819

Agent for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550

EIG/nr

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(REV. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
955-10 P/CON/DIV

SERIAL NO.
10/627,408

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT
Suthanthiran, et al.

CONFIRMATION NO.
2823

(Use several sheets if necessary)

FILING DATE
July 25, 2003

GROUP
1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		M. Maluccio, et al., "Angiotensin II Receptor Blockade: A Novel Strategy to Prevent Immunosuppressant-Associated Cancer Progression", <i>Transplantation Proceedings</i> (2001) Vol. 33, pp. 1820-1821.
		Hojo, et al., "Cyclosporine induces cancer progression by a cell-autonomous mechanism", <i>Nature</i> (1999) Vol., 397, pp. 530-534.
		Gary J. Nabel, "A transformed view of cyclosporine", <i>Nature</i> (1999) Vol. 397, pp. 471-472.
		Khanna, et al., "Regulation of new DNA Synthesis in Mammalian Cells by Cyclosporine", <i>Transplantation</i> (1994) Vol. 57, pp. 577-582. (Abstract)
		Kim, et al., "Immunosuppressive effects of 2-acetylaminofluorene and 2-aminofluorene on murine splenocytes culture", <i>Drug Chem Toxicol</i> (1989) Vol. 12, pp. 297-311. (Abstract)
		Tschmelitsch, et al., "Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil)", <i>Cancer Res</i> (1997) Vol. 57, No. 11, pp. 2181-2186. (Abstract)
		Baselga, et al., "Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies", <i>J. Natl. Cancer Inst.</i> (1993) Vol. 85, No. 16, pp. 1327-1333. (Abstract)
		Wolf, et al., "Angiotensin II-induced Hypertrophy of Cultured Murine Proximal Tubular Cells is Mediated by Endogenous Transforming Growth Factor- β ", <i>J. Clin. Invest.</i> , (1993) Vol. 92, pp. 1366-1373.
		Paine-Murrieta, et al., "Human tumor models in the severe combined immune deficient (<i>scid</i>) mouse", <i>Cancer Chemother Pharmacol</i> (1997), Vol. 40, pp. 209-214.
		Volpert, et al., "Captopril Inhibits Angiogenesis and Slows the Growth of Experimental Tumors in Rats", <i>J. Clin. Invest.</i> (1996) Vol. 98, pp. 671-679.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.